Bengaluru, June 30 -- The shares of this leading pharmaceutical company are in focus after the company secured the USFDA's approval for its key drug used to treat ovarian cancer. In this article, we will dive deep into its details.

With a market capitalisation of Rs 20,494 crores, the shares of Alembic Pharmaceuticals Ltd are currently trading at Rs 1,043 per share, down by 19.53 percent from its 52-week high of Rs 1,296.15 per share. Over the past five years, the stock has delivered a poor return of 13.58 percent.

The firm disclosed in a stock exchange document that it has been granted final clearance from the US FDA for its generic version of Doxorubicin Hydrochloride Liposome Injection.

The drug will be supplied in 20 mg/10 mL and 5...